Peptides & the FDA review: your questions, answered

Not on the July 2026 agenda. A later review is anticipated (reported as early 2027); no official FDA date was confirmed as of July 2026.^{1 2}

Yes - as a topical cosmetic ingredient, which is regulated differently from injectable drugs. The compounding review concerns the injectable form.¹

Topical GHK-Cu is sold as a cosmetic ingredient. The injectable form is not an FDA-approved drug and has no cleared compounding pathway; it was removed from Category 2 (injectable) in April 2026 but is not on the July 2026 agenda.^{2 1}